Biocartis Group NV (EUR)
BCART
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range4.53 | 4.74
52-Wk Range- | -
Last Close4.62
Mkt Cap (m)260.20
Dividend yield-
ISINBE0974281132
Volume78,749.00
Exchange VenueBRU

Company Profile

Biocartis Group NV along with its subsidiaries develops proprietary molecular diagnostics platform offering molecular information from any biological sample, enabling fast and effective diagnostics treatment selection and treatment progress monitoring.

Key Information
Price/Earning-
Price/Book3.08
Price/Sales6.91
P/CF-
Rev Growth (3 year avg)45.73
EPS Growth (3 year avg)-
Operating Margin % -147.81
Net Margin %-171.10
Return on Equity-74.57
Debt/Equity1.97

Documents

Prospectus
en 14/04/2015
Annual Report
en 31/12/2019

Please refer to the below issuer website for further documents.

https://www.biocartis.com

Financials

Income Statement
EUR201420152016201720182019
Revenue (m)8.4813.3312.1020.9627.8137.44
Operating Income (m)-29.17-39.66-50.17-43.59-46.80-55.35
Net Income (m)-9.12-39.80-49.78-41.96-48.15-64.07
Basic EPS-0.23-1.07-1.21-0.93-0.94-1.14
Avg. Diluted Shares Outstanding (m)40.4537.0641.0245.1551.1756.07
Balance Sheet
EUR201420152016201720182019
Current Assets (m)33.14118.10100.14133.0990.78214.63
Non Current Assets (m)19.8730.2841.1648.1048.6053.70
Total Assets (m)53.01148.38141.31181.19139.39268.32
Current Liabilities (m)17.7127.8814.9115.8020.2823.18
Total Liabilities (m)------
Total Equity (m)20.28114.9296.89132.2487.3584.48
Cash Flows
EUR201420152016201720182019
Operating Cash Flows (m)-35.88-23.36-53.31-41.41-41.99-54.25
Capital Expenditure (m)-2.77-9.61-11.05-4.32-5.83-2.52
Figures are quoted in EUR unless stated otherwise
-
No change
4.62
Last Price